18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients with EGFR Activated Recurrent Glioblastoma

NCT03732352 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

12

Enrollment

OTHER

Sponsor class

Conditions

EGFR Gene Amplification
EGFR Gene Mutation
Glioblastoma
Recurrent Glioblastoma
Supratentorial Glioblastoma
TP53 Wt Allele

Interventions

OTHER: Fludeoxyglucose F-18
DRUG: Osimertinib
PROCEDURE: Positron Emission Tomography

Sponsor

Jonsson Comprehensive Cancer Center

Collaborators

[object Object]